Redirecting To American Academy of Dermatology
Let your virtual meeting experience begin! Stream 75+ educational sessions covering the full breadth of dermatology. Browse the agenda below and navigate to the session you’d like to watch, then simply expand the title and click “watch on-demand”. Once you’ve completed the session, you can claim CME under the “Resources” tab above. You can view sessions as many times as you’d like, even after claiming CME credit. All content, with the exception of the Live Demonstration sessions and select Industry Sessions, will be available on-demand through July 12.
AAD gratefully acknowledges the support from Bristol Myers Squibb.
Dani Shapiro is the author of the best-selling memoir Inheritance. In the spring of 2016, through a genealogy website, Dani Shapiro received the stunning news that her father was not her biological father. Inheritance is a book about secrets — secrets we keep from one another in the name of love. It speaks to our extraordinary moment, when science and technology have outpaced not only medical ethics but also the capacities of the human heart to contend with what we discover.
*Please note this recording is only available until May 7th.
AAD supporters are invited to this donor appreciation VMX launch event for a brief presentation hosted by AAD leadership, followed by small group discussions on timely topics with industry partners. This event will take place in Zoom and is accessible from the AAD Donor Appreciation booth (under the AAD Showcase dropdown menu).
Take a quick 15-minute wellness break to relax and re-energize during AAD VMX. You can access four personal wellness videos that will help you refresh during the meeting from our Wellness Center.
AAD’s got talent! Be sure to tune into the VMX Talent Show to see your skilled colleagues.
Bristol Myers Squibb invites you to a virtual symposium where 3 leading experts in the field of dermatology will explore the unmet needs in the management of psoriasis and the role of TYK2 in the pathology of psoriasis and other autoimmune diseases. Despite the availability of treatment options, many patients with psoriasis are not treated or are undertreated.1,2 Shared decision-making and understanding patient preferences are crucial for treatment success.2,3 The TYK/JAK family members play a role in both immune and broader systemic cytokine signaling.4 For psoriasis, TYK/JAK-mediated signaling is involved in immune activation and recruitment to psoriatic lesion sites, and the perpetuation of lesions.4,5 Beyond psoriasis, these pathways play an important role in the pathology of psoriatic arthritis, inflammatory bowel diseases, and lupus, among other disorders.7-10 This demonstrates how a key pathogenic signaling axis may be shared across a range of different immune-mediated inflammatory diseases.6-10 References: 1. Armstrong AW et al. Dermatol Ther (Heidelb). 2017;7:97-109. 2. Lebwohl MG et al. Am J Clin Dermatol. 2016;17:87–97. 3. Alcusky M et al. Dermatol Ther (Heidelb). 2017;7:463–483. 4. Bannerjee S et al. Drugs. 2017;77:521-546. 5. Hawkes JE et al. J Allergy Clin Immunol. 2017;140:645-653.
Come hear an expert discussion on the evaluation and management of a patient with uncontrolled moderate-to-severe atopic dermatitis and a treatment option for your appropriate patients.
The goal of the session is to highlight "elusive" and clinically overlapping presentations of CTCL and to engage the audience in discussions around how to effectively work up, diagnose and treat varying subtypes of CTCL.
Dermatologists often feel overwhelmed with constantly changing coding and documentation requirements as well as burdensome insurer and regulatory mandates. Insurers place hurdles to appropriate reimbursement for services and are reviewing medical records with increasing frequency. Worse yet, a dermatologist may be faced with a serious audit or recoupment demand. This session will provide dermatologists with an update of the latest coding and documentation guidelines; examine those practice and coding areas most at risk for review or audit; and outline a plan for responding to insurer medical audits.
This session aims to better enable dermatologists to provide medically appropriate, culturally sensitive, and culturally humble care to LGBTQ/SGM persons. Covering basic and advanced knowledge domains in LGBTQ/SGM healthcare, topics include skin cancer in sexual minority populations; dermatologic management of gender diverse individuals with a focus on acne, hair removal considerations, minimally invasive procedures, and the role of contraception and how to manage contraception as part of dermatology therapeutics in the gender diverse patient; and state and federal policy framework for contextualizing the impact of discrimination and its intersection with access to affirming care and health outcomes.
Content for the Live Demonstration is Live only and will not be listed for On Demand viewed after the scheduled session time.
This session will include demonstration of newly FDA-approved tools to augment existing nonsurgical rejuvenation. Attendees will have the unique opportunity to see live patient assessment and treatments along-side demonstration of pertinent anatomy on a dissected cadaver - techniques have evolved to require injections at various tissue planes, therefore understanding anatomy is extremely important in order to avoid complications and maximize patient outcomes. Live patient demonstrations will include augmentation with dermal fillers, treatment of submental fullness, and optimal use of neuromodulators.
Neurocutaneous dysesthesias can be a challenge to diagnose and treat. We look to the literature for an evidence-based three part talk on some difficult diseases in this field: 1) what's new in neurocutaneous dysesthesias, 2) vulvodynia pearls, and 3) an update in anogenital pruritus.
Appropriate use criteria (AUC) provide physicians guidance in test selection, and can affect health care delivery, reimbursement policy, and physician decision-making. The American Society of Dermatopathology with input from the American Academy of Dermatology and the College of American Pathologists developed AUC for 12 tests used in dermatopathology. The recommendations of appropriateness will be reviewed with an emphasis of clinical scenarios that affect the practicing dermatologist.
This session explores different traditions and their approaches to dermatologic problems. From botanicals, ayurvedic approaches, herbs, and mind-body therapies, there is growing interest in these complementary therapies. Importantly, there also exists a body of evidence, and we will carefully review the extant literature.
The skin is frequently reflective of internal disease. This session will update the attendees with new aspects of such diseases and prepare them for developing effective, efficient plans for evaluation of such patients. In addition, attendees will be provided with a therapeutic scheme for cost-effective management. Off-label uses of medications will occur, but we will use the best level of evidence available for the basis of the therapeutic discussions.
We will review the state of the art in our current understanding of the pathogenesis of acne and rosacea and compare the added benefit of new treatment options, including pipeline drugs.
This session is intended to provide the attendee with an overview of the expanding systemic, non-surgical options for advanced non-melanoma skin cancer, for which there is no standardized management approach. While surgery is a viable option for many patients, it also may carry the risk of cosmetic and functional incapacity. Available treatments, both systemic and topical will be discussed with a focus on the data and an eye toward future developments. Attendees should be more comfortable discussing options with their patients and colleagues for the management of advanced nonmelanoma skin cancer.
Generalized pustular psoriasis (GPP) is genetically and clinically distinct from psoriasis vulgaris, yet may still be incorrectly considered the same disease. Recent findings have uncovered greater genetic information with respect to differences in generalized pustular psoriasis and psoriasis vulgaris. Uncontrolled activation of the IL-36 pathway can drive inflammatory pustular skin diseases. Targeting this pathway may prove a feasible approach to treating generalized pustular psoriasis.
Incredible therapeutic advances in psoriasis have occurred in the last 20 years, most of which stemmed directly from scientific discoveries in the immunopathogenesis of this disease. Similar scientific work along with subsequent translational studies are now rapidly occurring in atopic dermatitis. Here, Dr. Andrew Blauvelt will review key recent scientific findings on atopic dermatitis, discuss how this work is being translated into clinical studies with new targeted therapies, and review important differences in psoriasis drug development versus atopic dermatitis drug development, highlighting the challenges that we still face with treatments for atopic dermatitis.
Editors of our key journals will discuss advances in medical, surgical and pediatric dermatology
In this session we will hear from experts in COVID-19 dermatology. This symposium will serve as an overview of key topics in COVID-19, ranging from COVID skin manifestations, COVID-19 and skin of color, COVID-19 vaccines, COVID-19 and biologics, and affects of COVID on dermatology training and practice.
During the session, off-label use of biologic and other specialty drugs will be reviewed. The aim is to help the practioner optimize the delivery of appropriate treatments for patients. Medications to be discussed include TNF-alpha inhibitors, anti-IL17 antibodies, anti-IL23 biologics, dupilumab, apremilast, and JAK inhibitors.
This interactive forum will cultivate creativity and collaboration among learners. The forum features an overview of the innovation process through a series of dynamic didactic talks on how to identify clinical problems and unmet needs, how to brainstorm and prototype potential solutions, how to identify stakeholders, how to to collaborate with researchers and how to pitch solutions for further development and commercialization. The didactic talks will be punctuated with small, interactive, breakout sessions where learners can practice innovation in real-time and apply it to a clinical problem that is personally meaningful to them.
Using case examples, this session will review key clinical points and updates relevant to genetic skin disorders in a dermatology clinic.